Mibg (123i) Curium Netherlands

Iobenguane I-123, the active ingredient in Mibg (123i) Curium Netherlands, is a radiopharmaceutical presented as an injectable solution for intravenous use. It enables visualization of sympathetic nerve activity for cardiac and neuroblastoma imaging in patients undergoing nuclear medicine studies.

GNH USA supplies Mibg (123i) Curium Netherlands as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and nuclear medicine clinics worldwide.

Mibg (123i) Curium is used in nuclear medicine to assess sympathetic nerve function in specific disease contexts. - Cardiac sympathetic innervation imaging: visualizes myocardial sympathetic nerve distribution to aid diagnosis and risk assessment. - Heart failure risk stratification: provides functional data on cardiac sympathetic activity to help guide therapeutic decisions. - Neuroblastoma imaging: detects neuroblastoma lesions by targeting the norepinephrine transporter in tumor cells.

Adverse reactions may occur following intravenous administration of Iobenguane I-123.

Common Side Effects: - Nausea: mild and transient. - Headache: occasional during or after injection. - Flushing: brief skin reddening. - Injection site pain: mild discomfort at the venipuncture site. - Transient hypertension: short‑lived rise in blood pressure. - Dizziness: mild light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Radiation‑induced tissue injury: localized damage at high exposure sites. - Arrhythmia: abnormal heart rhythm. - Severe skin reaction: extensive rash or urticaria. - Thyroid dysfunction: abnormal thyroid hormone levels due to iodine exposure.

Prior to use, clinicians should evaluate patient‑specific factors and follow safety guidelines. - Pregnancy: avoid unless clearly needed, as fetal radiation exposure is possible. - Breastfeeding: discontinue nursing for an appropriate interval after administration. - Radiation safety: limit staff exposure and follow local radiation protection protocols. - Renal function: assess because the tracer is cleared renally. - Thyroid blocking: consider iodine blockade in patients at risk for thyroid uptake. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iobenguane I-123 may interact with other agents that affect norepinephrine pathways or iodine handling.

Major Interactions (Avoid): - Sympathomimetic drugs (e.g., epinephrine): compete for NET uptake and may reduce image quality. - Iodine‑containing contrast agents: can interfere with tracer distribution and imaging interpretation. - Thyroid hormone therapy: may alter iodine metabolism and affect tracer uptake.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may modify sympathetic activity and influence tracer accumulation. - Calcium channel blockers: could affect cardiac perfusion and imaging results. - Diuretics: may change renal clearance of the radiotracer.